Literature DB >> 21609311

Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.

Dharmendra Kumar Maurya1, Rie Ayuzawa, Chiyo Doi, Deryl Troyer, Masaaki Tamura.   

Abstract

The effect of SN-38 was evaluated on multiple lung cancer cell lines. It inhibits anchorage-dependent and -independent growth as monitored by MTT and soft agar colony assay, respectively. SN-38 collapsed the mitochondrial membrane potential (MMP), arrested cells in S- and G2-phases of the cell cycle, and induced apoptosis via activation of caspase 3 and PARP. A single injection of 2 mg/kg body weight of SN-38 caused a significant reduction of lung cancer xenografts. These findings indicate that SN-38 induces apoptosis in the lung cancer cells effectively. Thus, SN-38 can potentially be an effective therapeutic agent against lung cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21609311      PMCID: PMC3133571          DOI: 10.1615/jenvironpatholtoxicoloncol.v30.i1.10

Source DB:  PubMed          Journal:  J Environ Pathol Toxicol Oncol        ISSN: 0731-8898            Impact factor:   3.567


  41 in total

Review 1.  A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol.

Authors:  J Gusman; H Malonne; G Atassi
Journal:  Carcinogenesis       Date:  2001-08       Impact factor: 4.944

Review 2.  Novel therapies for the treatment of non-small cell lung cancer.

Authors:  David H Johnson; Joan H Schiller
Journal:  Cancer Chemother Biol Response Modif       Date:  2002

Review 3.  Cellular stress response and apoptosis in cancer therapy.

Authors:  I Herr; K M Debatin
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

4.  Induction of apoptosis in human lung cancer cells by curcumin.

Authors:  G Radhakrishna Pillai; Anand S Srivastava; Tarek I Hassanein; Dharam P Chauhan; Ewa Carrier
Journal:  Cancer Lett       Date:  2004-05-28       Impact factor: 8.679

5.  Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.

Authors:  Kimihiko Ohtsuka; Shoichi Inoue; Masayo Kameyama; Akio Kanetoshi; Toru Fujimoto; Kazuo Takaoka; Yoshikazu Araya; Akira Shida
Journal:  Lung Cancer       Date:  2003-08       Impact factor: 5.705

6.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Authors:  Y H Hsiang; R Hertzberg; S Hecht; L F Liu
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

9.  Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu.

Authors:  C M Tsai; K T Chang; J Y Chen; Y M Chen; M H Chen; R P Perng
Journal:  Cancer Res       Date:  1996-02-15       Impact factor: 12.701

Review 10.  Perspectives on cancer therapy: cell cycle blockers and perturbators.

Authors:  Yoh Dobashi; Takuo Takehana; Akishi Ooi
Journal:  Curr Med Chem       Date:  2003-12       Impact factor: 4.530

View more
  6 in total

1.  Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines.

Authors:  Kazuaki Matsuoka; Teiji Takechi
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  A novel irinotecan derivative ZBH-1207 with different anti-tumor mechanism from CPT-11 against colon cancer cells.

Authors:  Dawei Zhao; Di Wu; Gengyue Zhang; Yongqi Li; Weiguo Shi; Bohua Zhong; Hong Yu
Journal:  Mol Biol Rep       Date:  2022-06-29       Impact factor: 2.742

3.  Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway.

Authors:  Mohammad Hassan Hodroj; Achraf Jardaly; Sarah Abi Raad; Annalise Zouein; Sandra Rizk
Journal:  Cancer Manag Res       Date:  2018-05-10       Impact factor: 3.989

4.  A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.

Authors:  Jianling Zou; Shuang Li; Zuhua Chen; Zhihao Lu; Jing Gao; Jianyin Zou; Xiaoting Lin; Yanyan Li; Cheng Zhang; Lin Shen
Journal:  Cell Death Dis       Date:  2018-05-31       Impact factor: 8.469

5.  Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.

Authors:  Tao-Chieh Yang; Shih-Jung Liu; Wei-Lun Lo; Shu-Mei Chen; Ya-Ling Tang; Yuan-Yun Tseng
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

6.  Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.

Authors:  Theodore Hu; Young Min Chung; Michelle Guan; Michael Ma; Jessica Ma; Jonathan S Berek; Mickey C-T Hu
Journal:  Sci Rep       Date:  2014-07-24       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.